Announced
Synopsis
Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, agreed to acquire Kezar Life Sciences, a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, for $132.5m. "We are glad to form a partnership with Kezar through our cooperation on zetomipzomib, which will add to our existing renal pipeline, and help solidify Everest's leading position in renal and autoimmune diseases in Asia," Rogers Yongqing Luo, Everest Medicines Chief Executive Officer.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.